Health Canada has approved Appili Therapeutics’ application to begin Phase 3 trials for tablets that should help prevent COVID-19 in people exposed to the disease.
The Halifax-based drug discovery company issued a statement Tuesday saying it had initiated its tests to evaluate Avigan, the name of a tablet that contains Favipiravir, a broad-spectrum antiviral that Appili has licenced from Fujifilm Toyama of Japan. Appili also expects to begin Phase 3 trials in the U.S. soon after the Food and Drug Administration allowed it to submit an amendment to its application.
“Addressing infections and